BioChaperone insulin lispro + Humalog®
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Sep 1, 2015 → Jan 1, 2016
NCT ID
NCT02562326About BioChaperone insulin lispro + Humalog®
BioChaperone insulin lispro + Humalog® is a phase 1 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02562326. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02562326 | Phase 1 | Completed |
| NCT02562313 | Phase 1 | Completed |
| NCT02528396 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus